

AbCheck: Antibody Discovery Deal

First validation of technology and business approach

Plzen, Czech Republic; October 05, 2010: AbCheck s.r.o., a Czech based company specializing in the discovery and development of novel human high affinity antibodies, announced today an antibody discovery deal with Eli Lilly and Company, a global pharmaceutical company.

Under the agreement, AbCheck will use its three antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The three distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, will pay AbCheck discovery fees and development milestone payments. Other financial and deal terms are not disclosed.

“This discovery deal with Lilly is an important validation of our antibody discovery and business approach,” said Dr Volker Lang, Managing Director of AbCheck. “Signing our first deal with such a significant company so soon after setting up AbCheck, has certainly given us a tremendous boost of confidence that AbCheck is following a successful business strategy.”

AbCheck’s libraries are designed as universal tools for the isolation of antibodies against all possible targets. This breadth of targets differentiates the libraries from immunized libraries, which are restricted to only a minor fraction of therapeutically interesting target antigens.

For further information please contact:

AbCheck s.r.o.
Dr. Volker Lang (Managing Director)

MC Services AG
Birte Stein

Phone: +420 378 051500
Fax: +420 378 051506
E-Mail: V.Lang@abcheck.eu

Phone: +49 89 210 228 12
Fax: +49 89 210 228 88
E-Mail: Birte.Stein@mc-services.eu

About AbCheck s.r.o.:

AbCheck, founded in 2009, specializes in customized antibody discovery and screening for therapeutic applications. Based on three different fully human antibody libraries, the technology portfolio covers all aspects regarding the generation of therapeutic antibodies from research to lead optimization. The use of three highly diversified libraries enables AbCheck to isolate very specific human antibodies against virtually any target from a portfolio of more than 10 billion different antibodies. The company has isolated more than 25 different therapeutic antibody drug candidates with characteristics such as high affinity and high specificity for even the most difficult targets. AbCheck s.r.o. is a spin-off of Affimed Therapeutics AG and is headquartered within the technology park in Plzen, Czech Republic.